Prescription guidelines in cardiology - frison roche - 9782876715547 -
Prescription guidelines in cardiology 

Prescription guidelines in cardiology

Cardiological therapy is refined day by day on the basis of clinical trials and meta-analyses, the results of which, insufficiently known or applied, have demonstrated and justified with an almost absolute strength of evidence the value of a given molecule depending on the patient's clinical state.The proposed treatment guidelines are directly derived from results of more than [...]
[lire le résumé du livre]

Auteur : 

Editeur : Frison Roche

Date parution :  (4ème édition)

 Multilingue : | Anglais |


Préface :
Pr. Pierre GODEAU
Reliure :
Broché
Nbr de pages :
279
Dimension :
11,5 cm × 17,0 cm × 1,5 cm
Poids :
270 gr
ISBN 10 :
2876715546
ISBN 13 :
9782876715547
28,00 €
Disponible expédié
sous 4 à 8 jours

Paiements sécurisés
CB Google/Apple Pay, Chèque, Virement
0.01€ à partir de 35€ en France métropolitaine
Satisfait ou remboursé sous 14 jours ouvrés

Quel est le sujet du livre "Prescription guidelines in cardiology"

Cardiological therapy is refined day by day on the basis of clinical trials and meta-analyses, the results of which, insufficiently known or applied, have demonstrated and justified with an almost absolute strength of evidence the value of a given molecule depending on the patient's clinical state.

The proposed treatment guidelines are directly derived from results of more than four hundred large-scale clinical trials and one hundred and a hall studies and meta-analyses, amplified and strengthened by the main guidelines of scientific societies, usually American or European.

These treatment guidelines provide the prescriber with a scientific and practical guide to the procedures and cules that now govern modern cardiological therapy in lise with the most recent scientific data.

En suivant ce lien, retrouvez tous les livres dans la spécialité Cardiologie médicale.

Sommaire et contenu du livre "Prescription guidelines in cardiology"

Table of contents


Preface... 5

Foreword.... 9

Chapter 1 -Cardiovascular risk factors.. 11

A-Hypertension................................. 11

Definitions and diagnosis............ . 13

Non-pharmacological treatment 16

Pharmacological treatment . 18

HT and lVH................... 34

Hl and dyslipidemia.... 36

HT of the elderly 38

Hl and diabetes............................. 41

Hl and coronary heart disease.. 41

Hl and stroke 42

Hl and renal failure ', ,_. ' , ,.,..,.................. . ,..,.., , 43

HT and pregnancy .. , , ,',.. ,.,.......... 44

~;s~~':n~t~tn~f~I~~~ ·p·~~~~·~·;ë·~ont;~ï:: :~
8 -Dyslipidemia. 53
Non-pharmacological treatment ,. S5
Pharmacological treatment.. S6

Factual data.. .. ,............... 53

Dyslipidemia and HT 66

Dyslipidemia and diabetes 66

Chapter 2 -Diabetes..... 71

Factual data....................... 71

Definitions and diagnosis.......... . . 72

Cardiovascular risk reduction.. 73

Diabetes and hypertension 83

Diabetes and dyslipidemia 91

Oiabetes and coronary heart disease 96

Prevention of diabetes.. 98

Chapte, 3 -Stable angina. . 101

~,~t~~~?~~~1 ~[~~~i~i;~h~;;;i~.~~~~ï; .• :::............................................... . ~ g~

The prescription for patients with stable coronary heart disease.... .. 106

Myocardial revascularization .. 106

Chapter 4 -Acute coronary syndromes without persistent ST-segment elevation.. 113

Factual data 113

Risk stratification................................................... 114

Earl)' invasive strategy V5 conservative strategy 115

Antlthrombotic therapy 119

Anti-ischemic therapy 129

Coronary angioplasty V5 coronary artery bypass graft.. 130

Other drugs . 131

Chapter 5 -MyocardiaJ infarction with persistent ST-segment elevation. 135

Factual data................................................. 135

Early restoration of coronary perfusion.. 135

Primary angioplasty 140

Adjuvant therapy .. 148

Chapter 6 -Post-myocardial infarction.. 159

BASIC treatment and control of risk factors .. 159

~~r:n~~~~~·(·~·;d;o·~·~·~t·~·;~~~iëfib·~iii~t·~~·(ïëD):::: ::: :::::::::::: ~~;
Chapter 7 -Valvular heart disease 173

Chapter 8 -Pericardites. 175

Chapter 9 -Chronic heart failure.. 177

Prevention 177

Non-pharmacological treatment 178

Pharmacological treatment...... 179


~~1~~;~b~~nc~~~~~~~i~r~dt:f~b~Firat'~~'(ïëDj ~~~
Resynchronization and ICO 200
Surgical treatment 201 Ultrafiltration.................... .. 205
Improved follow-up . 205
Chapter 10 -Atrial fibrillation.... .. 209
Cardîoversion for atrial fibrillation . 209
~~~~~? 6/s~~~~trh~~~~ ::~~~~~~Ii~f~~~t·;i~~iar··~at~·::··· .:: ~U
Antithrombotic therapy. . 217
Chapter 11-Venous thromboembolism 225
Deep vein thrombosÎs. . . 225 Pulmonary embolism .. . 232
Chapter 12 -Stroke prevention ...... .. 239 Primary prevention of atherothrombotie stroke or TIA..... . 239 ~~~~~Ja~;~vr~~~~~~~~fa~h'~~~~~~~~~o~~~st·~~k~·ë·~·TiA· ::::::::::::.: ~:1 Seeondary prevention of embolie stroke or TIA. . 249 Correction of symptomatic carotid artery stenosis.. . . 249 Correction of asymptomatic carotid artery stenosis.. 251
Tables Causes of refractory HT .... 47 Cockcroft and Gault formula . 47 levey formula (MDRD) . 48 Rationale for fixed combinations of antihypertensives .. 48 Secondary hypertension .. 49 New BHS-NICE guideline, . 49 Evaluation of the ten-year eardiovascular risk -The Framingham equation .. 50 Evaluation of the ten-year cardiovascular risk -The SCORE grid 51 Conversion factors . 66 Friedewald's formula .. 66 Body mass index . 67 Risk of diabetes on statins . 67 Guidelines on the management of dyslipidemjc patients . 6B 70
~:it~~~~~es~~fd~~~f.~.~~:.i.~~.:::::::::::::::::::::::::::::::::::::::::::::::::: .. 100 Silent myocardial ischemia -Cohn's classification.. 110 SYNTAX 'core. ........ .... 110 Angina pectoris: functional classification 111 EDRF, NO and nitrates . 111 European guidelines on the treatment of stable angina peeloris. .. .. 112 TIMI risk score in ACS without ST-segment elevation . 133 Killip's classification of heart failure during acute myocardial infarction . 157 Non-steroidal anti-inflammatory druC)s (NSAIDs) inerease the eardiovaseular risk. 157
~~:a~;~;~f~~;~~~~~~~~Oa~~~j~I?~:::;.~~~s~if·i~aù·~~·:::: 158 171
Resuscilalion procedures . 172
Stages of heart failure .. 207
Measurement of leh ventricular ejection fraction (lVEF) 208
Heart failure with preserved systolic function . .. 208
Bleeding risk with oral anticoagulants: Beyth's score.... . .. 221
Classification of atrial fibrillation . .. 222
CHADS2 ,core and CHADS2DS2-VASc .. .. 222
Embolie risk .... 223
HAS-BlED Score .. .. .. 223
Target recommendations (Afssaps 9uidelines, 2009) .. ~~~ri~~~~i~~I~~~~~e:rf:~~1i~s~(~~re~kydinede~).i~ ..~~~~~~.~~.i~::: .. .. .. 235 235 ......... 236
Miller's index .. .... 237
Pulmonary embolism: essential concepts ........ Right heart thromboembolism ... .. .. 238 238
Index. .............. 253


    Avis clients sur Prescription guidelines in cardiology - frison roche -

    (Ils sont modérés par nos soins et rédigés par des clients ayant acheté l'ouvrage)
    Donnez votre avis
     
    Controler les cookies